Bright Minds Biosciences to Present 5-HT2 Agonist Pipeline at Upcoming Investor Conferences
核心洞察
Bright Minds Biosciences (搜索) (NASDAQ: DRUG) will present at the Cantor Global Healthcare Conference on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
The company is developing highly selective 5-HT2 agonists for drug-resistant epilepsy (搜索), Prader-Willi Syndrome (搜索), depression (搜索), and other central nervous system disorders.
Bright Minds' pipeline targets 5-HT2C (搜索), 5-HT2A (搜索), and combined 5-HT2C/A receptors, with additional programs in chronic pain and impulse control disorders such as binge eating.
Bright Minds Biosciences (搜索), Inc. (NASDAQ: DRUG), a biotechnology company focused on developing highly selective 5-HT2 agonists for neurological and psychiatric disorders, announced it will present at two upcoming investor conferences. The company will present at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, at 1:35pm ET, and at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 4:00pm ET.
Bright Minds describes itself as a pioneering company developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy (搜索), Prader-Willi Syndrome (搜索), depression (搜索), and other central nervous system (CNS) disorders. The company has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors, which it states has provided a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry.
Pipeline and Therapeutic Focus
Bright Minds Biosciences (搜索) is a pre-clinical stage Canadian biosciences company dedicated to developing innovative medicines for severe and life-altering neurological and psychiatric conditions. The company's core focus is on creating specialized 5-HT (serotonin) based therapies, aiming to improve patient outcomes in areas with significant unmet medical needs.
The company's main product pipeline consists of selective 5-HT receptor agonists, specifically targeting 5-HT2C (搜索), 5-HT2A (搜索), and combined 5-HT2C/A receptors. These drug candidates are being advanced for the treatment of various therapeutic areas, including epilepsy, chronic pain, and neuropsychiatric disorders, such as impulse control disorders like binge eating.
Research Collaborations
Bright Minds Biosciences (搜索) collaborates with prominent research institutions to further its development programs. These collaborations include the National Institutes of Health and the University of Texas Medical Branch.
Leadership and Clinical Expertise
The company's leadership team includes Chief Executive Officer Ian McDonald, who was appointed CEO in May 2019 and is a co-founder of the company. Dr. Stephen D. Collins, M.D., Ph.D., serves as Chief Medical Officer, having been appointed in January 2025. Dr. Collins brings extensive drug development and clinical expertise in epilepsy, having previously served as CEO of Biscayne Neurotherapeutics and CEO and President of Biscayne Pharmaceuticals. He also worked in Abbott Laboratories' Pharmaceutical and Hospital Products Divisions, where he developed drugs for various CNS indications, including Depakote. Dr. Collins has served on several boards of companies that developed epilepsy drugs, including Spinifex Pharmaceuticals, which was acquired by Novartis, and Engage Therapeutics, which was sold to UCB S.A.
Additional leadership includes Ryan E. Cheung as Chief Financial Officer and Corporate Secretary, Dr. Jan Pedersen as Chief Science Officer and Director, and Alex Vasilkevich as Chief Operating Officer and Senior Scientific Officer.